Comparing the current results to its competitors, Bristol Myers Squibb reported Revenue increase in the 1 quarter 2026 by 2.57 % year on year. The revenue growth was below Bristol Myers Squibb's competitors' average revenue growth of 10.15 %, achieved in the same quarter.
Bristol myers Squibb Company Net Income in the 1 quarter 2026 grew year on year by 8.77%, while most of its competitors have experienced a contraction in net income by -32.01 %.
Bristol Myers Squibb's Comment on Competition and Industry Peers
The company operates in a competitive environment alongside global research-based pharmaceutical firms, smaller research companies with narrower therapeutic focuses, and generic drug manufacturers. Key competitive factors include product efficacy, safety, ease of use, pricing, cost-effectiveness, marketing effectiveness, product labeling, customer service, and research and development of new products and processes. Sales are influenced by new clinical studies and regulatory exclusivity periods, which affect the timing of generic competition. Patent protections and regulatory exclusivity differ by country, impacting market exclusivity and competitive dynamics.
April 30, 2024
In a bid to expedite the development of drug targets, Scenic Biotech, a pioneer in modifier therapies for severe genetic disorders, has announced a research collaboration with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to identify target biology for indication selection and expansion, supporting Bristol Myers Squibb s efforts to advance their drug development pipeline.Under the terms of the agreement, Scenic Biotech will receive an upfront payment as well as potential additional payments contingent upon achieving certain milestones. This collaboration highlights the value that Scenic Biotech s expertise in modifier therapies can bring to accelerate the discovery and development of novel drug t...
April 22, 2024
Revolutionizing the field of immunotherapy, Bristol Myers Squibb and Cellares recently announced their collaborative venture on a worldwide capacity reservation and supply agreement, a business transaction valued at an upfront payment and milestones of up to $380 million. This partnership seeks to facilitate the expansion of CAR T cell therapies production in a move that promises to bring cell therapy to more patient groups more quickly.Headquartered in Princeton, New Jersey, and South San Francisco, California, respectively, the pharmaceutical giant Bristol Myers Squibb (NYSE: BMY) and Cellares, the leading Integrated Development and Manufacturing Organization (IDMO) focused on clinical and industrial-scale...
Publicly Traded Peers of Bristol myers Squibb Company
Cellectar Biosciences Inc Share Performance
-54.44%
One Year
Cellectar Biosciences Inc
Profile
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
HCW Biologics Inc is a biotechnology company that operates on a business model focused on the research, development, and commercialization of biologic therapies. The company primarily focuses on developing and manufacturing novel biological products for various medical conditions. Their business model involves collaboration with industry partners, conducting clinical trials, and securing regulatory approvals for the commercialization of their biologic therapies.
Sources:
Bristol myers Squibb Company’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bristol myers Squibb Company versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
